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discharge, left ventricular ejection fraction (LVEF) was measured with a radionuclide
technique.
Results: Results are shown in the Table. Data for pts with anterior MI in relation to
LDHQ48 (mean ± SD) and LVEF (mean ± SD) are shown separately. 
Conclusion: Not only TIMI 3 flow, but any increase in initial TIMI flow of the IRV is asso-
ciated with a better preserved LVEF, smaller enzymatic infarct size and higher MBG. Fur-
ther research, involving (pharmacological) treatment leading to improvement of initial 
patency of the IRV in pts with acute MI treated with PA, should be encouraged.
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1001-5 Blood-Borne Hematopoetic Cells of Monocyte Origin: 
Precursors to Neointimal Myofibroblasts After Coronary 
Artery Injury
Robert S. Schwartz, Arturo G. Touchard, Antoni Bayes-Genis, Minnesota Cardiovascular 
Research Institute, Minneapolis, MN
Background The origin of neointimal myofibroblasts following coronary artery injury
remains an intriguing, but unknown question.Since macrophages participate prominently
in neointimal formation through early colonization of arterial lesion sites, we questioned
the relationship between these cell lines. We thus studied whether monocyte/macroph-
age lineage cells contribute to neointimal cellular mass in a porcine model of thermal cor-
onary artery injury, a method that severely depletes normal medial cells and grows thick
neointimal hyperplasia by 28 days.
Methods and Results Thermal coronary artery injury using a radiofrequency-heated
angioplasty balloon caused medial smooth muscle cell necrosis and transformation of
the media into an acellular barrier. Neointimal hyperplasia developed at these injury sites
and was evaluated by light microscopy, electron microscopy and immunohistochemistry.
At day 3 after injury, blood monocytes adhered to the luminal side vessel wall only, and
infiltrated the fibrotic media. At day 14, 42 + 3.9% of neointimal cells had monocytic
nuclear morphology and expressed macrophage-specific antigen SWC3 (identified by
monoclonal antibody DH59B). Moreover, 9.2 + 1.8% of neointimal cells co-expressed
SWC3 and alpha-smooth muscle actin and had ultrastructural characteristics intermedi-
ate between macrophages and myofibroblasts. At day 28, 10.5 + 3.5% of cells expressed
SWC3 and 5.2 + 1.8% of cells co-expressed SWC3 and alpha-smooth muscle actin.
Conclusions These data suggest that monocyte/macrophage lineage cells of hemato-
poetic origin abundantly populate the neointima. Myofibroblasts within neointimal hyper-
plasia may originate from these precursor cells, thus suggesting a blood-borne route of
colonization.
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1001-6 Tissue Engineered Endothelial Cells Inhibit Early 
Events in the Vascular Response to Injury to Prevent 
Restenosis
Sahil A. Parikh, Brad C. Carofino, Amy C. Lee, Adam Groothuis, Philip Seifert, Helen M. 
Nugent, Elazer R. Edelman, Brigham and Women's Hospital, Boston, MA, 
Massachusetts Institute of Technology, Cambridge, MA
Background: Perivascular implantation of tissue engineered endothelial cells (TEEC)
after vascular injury profoundly inhibits neointimal hyperplasia (NIH). However, the time
course and mechanism of this effect is unknown. NIH in the rat carotid balloon injury
model occurs in a stereotypic stepwise progression. By developing genetically modified
TEEC expressing a “suicide gene,” we can control the time during which they exert their
effect. These TEEC can help identify the critical time window when the implants exert
their influence and may implicate their putative mechanism of action.
Methods: Bovine aortic endothelial cells (BAE) were transfected with the human herpes
simplex virus thymidine kinase (TK) gene to render them sensitive to ganciclovir (GCV).
BAE+TK were grown to confluence on Gelfoam and had the same growth kinetics and
biologic potency as control cells but were sensitive to GCV at low concentrations. The
BAE+/-TK were grown on Gelfoam and placed in the perivascular space around balloon
injured rat carotid arteries. Rats randomly received BAE+TK, BAE-TK, or nothing (con-
trol) after balloon injury. GCV was administered early (day 1-7), late (day 5-11) or not at
all. Rats were sacrificed and arteries examined histologically for NIH.
Results: Two weeks after injury, extensive NIH was observed in control animals with
intima:media area ratios of (0.80±0.19). Early administration of GCV to BAE+TK con-
structs significantly abrogated TEEC inhibition of NIH (0.45±0.06). NIH was still effec-
tively inhibited in animals with implants containing BAE-TK or BAE+TK that received
GCV late (0.11±0.04 and 0.19±0.05). Immunohistochemistry demonstrated the lethal
effect of GCV on BAE+TK.
Conclusions: The application of perivascular TEEC for only the first few days after injury
had a significant inhibitory effect on NIH. This suggests that the mechanism of action of
TEEC influences one of the early events in the vascular response to injury such as
inflammation or smooth muscle cell proliferation. Moreover, the use of this technique to
further elucidate biologic mechanisms will prove invaluable in the tissue engineering field.
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1001-7 The Use of Abciximab During Percutaneous Coronary 
Angioplasty in Patients With Acute Coronary Syndrome 
Improves the Microcirculatory Function: Results of a 
Prospective Randomized Study
Piotr Kwiatkowski, Alessandro Manzoli, Costantino Caroselli, Fabrizio Imola, Alessandro 
Pappalardo, Eugenio Caradonna, Alessandro Boccanelli, Francesco Prati, Cath Lab San 
Giovanni Hospital, Rome, Italy
Background. The use of abiciximab during PTCA in patients with acute coronary syn-
drome (ACS) was found to improve the clinical outcome, probably due to improvement of
post-PTCA microcirculatory function. This study was performed in patients with ACS to
define whether abciximab is capable to improve the post-PTCA microcirculation. Meth-
ods. We carried out a prospective randomized study including 136 patients with non ST
elevation ACS and scheduled for PTCA of the target lesion. Sixty-eight patients received
abciximab (group 1) whilst 70 patients were not treated with any GP IIb-IIa inhibitors
(group 2). All cases underwent QCA, CTFC and quantitative myocardial blush (MBG)
assessment, applying a software that evaluates the videointensity in a given region of
interest and using a 1 to 6 points (poor-optimal) perfusion scale. Results Group1 and
group 2 were comparable as regard incidence of diabetes (15% vs 18%), stenting ( 93%
vs 89%), procedures in the LAD( 44% vs 44% ). CKMB increase above range value was
found in a lower percentage of cases in the group with a 6 points MBG index in compari-
son with the group with MBG index < 5 points, although the difference was non significant
(3% vs 14% respectively; p=0.14). Pre- and post-PTCA %DS and CTFC were compara-
ble, whilst a statistically lower value of MBG post-PTCA was found in Group1 (p= 0.02).
Conclusions This study shows that the administration of abciximab improves the micro-
circulatory function in patients treated with angioplasty for acute coronary syndromes.
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1001-8 Long-Term Results of ISAR-REACT: A Randomized Trial 
Evaluating Abciximab in Patients With Elective 
Percutaneous Coronary Intervention After Pretreatment 
With a High Loading Dose of Clopidogrel
Helmut Schuhlen, Adnan Kastrati, Julinda Mehilli, Josef Dirschinger, Franz Dotzer, 
Jurrien ten Berg, Franz-Josef Neumann, Peter B. Berger, Albert Schomig, The ISAR-
REACT Investigators, Deutsches Herzzentrum, Munich, Germany, 1. Med. Klinik rechts 
der Isar, Munich, Germany
Background: The standard antithrombotic regimen after stent placement comprises clo-
pidogrel + aspirin. Clopidogrel however has a delayed onset of action which may be
accelerated by a loading dose. In addition, glycoprotein IIb/IIIa inhibitors have been
shown to reduce 30-day ischemic event rates. ISAR-REACT is a double blind, placebo-
controlled multicenter randomized trial evaluating whether abciximab is beneficial in low
and intermediate risk patients undergoing elective PCI after pretreatment with a high,
600 mg loading dose of clopidogrel at least 2 hours prior to PCI. Previous studies have
indicated that a maximal antiplatelet effect of clopidogrel is achieved with this regimen
within 2 hours. The primary endpoint (cumulative incidence of death, myocardial infarc-
tion, and urgent revascularization within 30 days) has been presented at the ACC 2003.
Methods: This analysis comprises prespecified secondary long-term endpoints, based
on a 12-month clinical follow-up of all patients, and a subset of 1600 patients with
planned repeat angiography after 6 months.
Results: The study enrolled 2159 patients undergoing PCI with stent placement between
May 2000 and February 2003: 1079 were randomly assigned to abciximab, 1080 to pla-
cebo. All patients had received 600 mg clopidogrel >2 hours prior to PCI. As previously
reported, the incidence of the primary endpoint at 30 days was 4.2% in the abciximab
group, and 4.0% in the placebo group (p=0.82). No significant differences were seen for
the rate of death, myocardial infarction, or bleeding complications. Profound thrombocy-
topenia occurred in 0.9% of the abciximab group versus none in the placebo group
(p=0.002). As enrolment ended in February 2003, clinical long-term follow-up and repeat
angiography are still ongoing.
Conclusions: With respect to the primary endpoint, this study indicates that in low to
intermediate risk patients undergoing elective PCI after pretreatment with 600 mg clopi-
dogrel, the additional administration of abciximab is associated with no clinically measur-
abel benefir within the first 30 days. Data on long-term 1-year clinical as well as 6-month
angiographic follow-up will be presented.
TIMI 0 (65%) TIMI 1 (10%) TIMI 2 (12%) TIMI 3 (13%)
MBG 2/3 (%) 75 81 89 96
LDHQ48 All MI
Anterior MI
1513 ± 1264
1816 ± 1404
1159 ± 1484
1601 ± 2126
1014 ± 956
1115 ± 1064
748 ± 700
808 ± 831
LVEF (%) All MI
Anterior MI
43 ± 11
36 ± 10
46 ± 11
39 ± 13
44 ± 11
41 ± 11
48 ± 11
46 ± 11
QCA %DSo:p> CTFC MBG
Pre-PTCA Post-PTCA Pre-PTCA Post-PTCA Post-PTCA
Group 1 74.9 ± 15.3 17.5± 14.9 30.1 ± 18.7 18.9 ± 8.7 3.6 ± 2.0
Group 2 71.7 ± 12.9 17.2 ± 8.8 23.7 ± 11.3 20.2 ± 8.2 2.9 ± 2.0
